Published on : Oct 06, 2016
ALBANY, New York, Oct 06, 2016: The global market for breast cancer monoclonal antibodies is examined in a detailed market research report recently added to the vast portfolio of ResearchMoz.us. The report, titled “Global Breast Cancer Monoclonal Antibodies Market 2016-2020,” states that the market will exhibit a healthy 8% CAGR over the period between 2016 and 2024.
Owing to the presence of high unmet opportunities in the fields of pharmaceutical and biotechnology, companies operating in these fields have increased their focus on research on monoclonal antibodies for breast cancer in the past few years. The report states that the breast cancer monoclonal antibodies market is one of the most promising segments of the global mAbs market as antibodies are rapidly becoming the preferred choice for treating breast cancer.
In terms of geography, the APAC breast cancer mAbs market will outpace other regional markets owing to better penetration of breast cancer monoclonal antibodies and biosimilars across emerging countries in the region such as India, Japan, China, South Korea, and Australia.
A continuously rising number of initiatives started by key market players with the aim of assisting patients in these countries is a key contributor to the increased consumption of mAbs in APAC. Additionally, the rising awareness regarding breast cancer and the treatment options available in the market will also help boost the overall demand for breast cancer monoclonal antibodies in APAC.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=816220
On the basis of mAbs type, the market is segmented into naked mAbs and conjugated mAbs. Of these, the segment of naked mAbs dominated, with a sweeping share nearly 91% of the global market in 2015. Some of the market’s most prominent naked mAbs include Herceptin (trastuzumab) and Avastin (bevacizumab), which are both approved by the US FDA.
On the basis of key end users of the breast cancer monoclonal antibodies, the report segments the market into hospitals and retail pharmacies. Of these, the segment of retail pharmacies dominated the market, accounting for a share of nearly 52% in 2015. Patients with breast cancer require monoclonal antibodies as a targeted therapy, helping promote the success rate of primary treatment by preventing the relapse of the disease. Monoclonal antibodies can be easily obtained from retail pharmacies and are the key source for hospital settings as well.
The competition in the global breast cancer monoclonal antibodies market is expected to intensify in the next few years owing to extension of product patents, technological innovations and an expected rise in the number of strategic mergers and acquisitions. A rising number of pharmaceutical companies across the globe that are adopting the course of these strategies are expected to exhibit inorganic growth over the forecast period and achieve vast gains. The pace of new players entering the market is high due to the vast growth potentials. However, stringent guidelines for manufacturing breast cancer mAbs are expected to restrict their growth.
Leading vendors in the market include F. Hoffmann-La Roche, Mylan, and Amgen. Other key vendors in the market include Bristol-Myers Squibb, DARA Biosciences, GlaxoSmithKline, Daiichi Sankyo, Celldex Therapeutics, Boehringer Ingelheim, Actavis, Hospira, Chugai Pharmaceutical, Sun Pharmaceutical Industries, ImmunoGen, Seattle Genetics, Pfizer, Novartis, and AstraZeneca.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on email@example.com